ICD via Oxaliplatin and Radiation

ACREDIT’s own Dr Simer Jit Bains has published a new paper looking into immune response in patients undergoing neoadjuvant oxaliplatin and radiation treatment. Dr Bains monitored the high-mobility group box-1 (HMGB1) protein, which is a circulating marker of immunogenic cell death, and found that patients at high risk of metastatic progression who did not experience a metastatic event were more likely to have also experienced higher levels of HMGB1. The protocol that produced the best outcome also included adjusting the amount of administered oxaliplatin during CRT, potentially improving response to treatment through maintenance of the immunogenic response during radiotherapy.

You can read Simer’s paper here.